Literature DB >> 9815939

Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression.

H Friess1, Y Yamanaka, M S Kobrin, D A Do, M W Büchler, M Korc.   

Abstract

The erbB-3 gene encodes a transmembrane protein that is related to the epidermal growth factor (EGF) receptor and erbB-2. We compared erbB-3 expression in the normal human pancreas, human pancreatic carcinomas, and cultured human pancreatic cancer cell lines. Northern blot analysis of total RNA revealed the anticipated 6.2-kb mRNA transcript in all 19 normal pancreatic samples. In 17 of 27 pancreatic cancers, there was a 6.7-fold increase (P < 0.001) in erbB-3 mRNA levels. Southern blot analysis did not reveal erbB-3 gene amplification. Four of six pancreatic cancer cell lines exhibited the 6.2-kb erbB-3 mRNA transcript, and all four cell lines coexpressed the epidermal growth factor receptor and erbB-2. Using a highly specific antibody, we determined that faint to moderate erbB-3 immunoreactivity was present in the ductal cells in the normal pancreas. In 47% (27/58) of the pancreatic cancers, there were many cancer cells with intense erbB-3 immunostaining. The presence of erbB-3 in the cancer cells was associated with advanced tumor stage and shorter survival postoperatively. These data indicate that a significant proportion of human pancreatic cancers overexpress erbB-3, and that erbB-3 may contribute to disease progression in this disorder.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9815939

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  37 in total

1.  Aberrant signaling pathways in pancreatic cancer: a two compartment view.

Authors:  Angela L McCleary-Wheeler; Robert McWilliams; Martin E Fernandez-Zapico
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

2.  ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma.

Authors:  J Spencer Liles; Juan Pablo Arnoletti; Ching-Wei D Tzeng; J Harrison Howard; Andrew V Kossenkov; Peter Kulesza; Martin J Heslin; Andrey Frolov
Journal:  Cancer Biol Ther       Date:  2010-09-30       Impact factor: 4.742

3.  HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.

Authors:  Marcia R Campbell; Dhara Amin; Mark M Moasser
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

Review 4.  Biology and management of pancreatic cancer.

Authors:  Paula Ghaneh; Eithne Costello; John P Neoptolemos
Journal:  Gut       Date:  2007-08       Impact factor: 23.059

Review 5.  The use of molecular technology in the differentiation of pancreatic cancer and chronic pancreatitis.

Authors:  S R Bramhall
Journal:  Int J Pancreatol       Date:  1998-04

6.  Growth factor receptors are differentially expressed in cancers of the papilla of vater and pancreas.

Authors:  H Friess; L Wang; Z Zhu; R Gerber; M Schröder; A Fukuda; A Zimmermann; M Korc; M W Büchler
Journal:  Ann Surg       Date:  1999-12       Impact factor: 12.969

7.  HER3 overexpression is a prognostic indicator of extrahepatic cholangiocarcinoma.

Authors:  Hee Jin Lee; Joon-Yong Chung; Stephen M Hewitt; Eunsil Yu; Seung-Mo Hong
Journal:  Virchows Arch       Date:  2012-10-02       Impact factor: 4.064

8.  HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells.

Authors:  Megan Jo Miller; Kevin C Foy; Jay P Overholser; Rita Nahta; Pravin Tp Kaumaya
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

9.  Prognostic significance of serum ERBB3 and ERBB4 mRNA in lung adenocarcinoma patients.

Authors:  Mirza Masroor; Jamsheed Javid; Rashid Mir; Prasant Y; Imtiyaz A; Mariyam Z; Anant Mohan; P C Ray; Alpana Saxena
Journal:  Tumour Biol       Date:  2015-08-09

10.  Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.

Authors:  Yassamine Lazrek; Olivier Dubreuil; Véronique Garambois; Nadège Gaborit; Christel Larbouret; Christophe Le Clorennec; Gaelle Thomas; Wilhem Leconet; Marta Jarlier; Martine Pugnière; Nadia Vié; Bruno Robert; Céline Monnet; Khalil Bouayadi; Hakim Kharrat; Philippe Mondon; André Pèlegrin; Thierry Chardès
Journal:  Neoplasia       Date:  2013-03       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.